Download PDF
Semin Liver Dis 2017; 37(04): 363-376
DOI: 10.1055/s-0037-1607451
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Multifunctional YY1 in Liver Diseases

Mengjie Zhang   *
1   Department of Pathophysiology, Third Military Medical University, Chongqing, People's Republic of China
2   Institute of Immunology, People's Liberation Army (PLA), Third Military Medical University, Chongqing, People's Republic of China
,
Yi Zhang   *
3   Department of Clinical Laboratory, 150th Hospital of People's Liberation Army (PLA), Luoyang, China
,
Shuang Yang
4   People's Hospital of Zunyi City, Bozhou District, Zunyi, China
,
Jian Zhou
1   Department of Pathophysiology, Third Military Medical University, Chongqing, People's Republic of China
2   Institute of Immunology, People's Liberation Army (PLA), Third Military Medical University, Chongqing, People's Republic of China
,
Weiwu Gao
1   Department of Pathophysiology, Third Military Medical University, Chongqing, People's Republic of China
2   Institute of Immunology, People's Liberation Army (PLA), Third Military Medical University, Chongqing, People's Republic of China
,
Xia Yang
2   Institute of Immunology, People's Liberation Army (PLA), Third Military Medical University, Chongqing, People's Republic of China
,
Di Yang
2   Institute of Immunology, People's Liberation Army (PLA), Third Military Medical University, Chongqing, People's Republic of China
,
Zhiqiang Tian
2   Institute of Immunology, People's Liberation Army (PLA), Third Military Medical University, Chongqing, People's Republic of China
,
Yuzhang Wu
2   Institute of Immunology, People's Liberation Army (PLA), Third Military Medical University, Chongqing, People's Republic of China
,
Bing Ni
1   Department of Pathophysiology, Third Military Medical University, Chongqing, People's Republic of China
› Author Affiliations
Further Information

Publication History

Publication Date:
22 December 2017 (online)

    Permissions and Reprints

Abstract

The transcription factor Yin Yang 1 (YY1) is a multifunctional protein that can activate or repress gene expression, depending on the cellular context. While YY1 is ubiquitously expressed and highly conserved between species, its role varies among the diverse cell types and includes proliferation, differentiation, and apoptosis. Upregulated YY1 expression is found in pathogenic conditions, such as human hepatocellular carcinoma and hepatitis B virus infection, and its roles in the molecular pathogenic mechanisms in liver (i.e., fibrosis, carcinogenesis, viral-induced injury) are currently being elucidated. The most recent studies have revealed that YY1 is deeply involved in such dysregulated cellular metabolisms as glycometabolism, lipid metabolism, and bile acid metabolism, which are all involved in various diseases. In this review, we will summarize the current knowledge on YY1 in liver diseases, providing a focused discussion on the characterized and probable underlying mechanisms, as well as a reasoned evaluation of the potential for YY1-mediated pathology as drug targets in liver disease therapies.

Keywords

YY1 - viral hepatitis - liver fibrosis - hepatocellular carcinoma - cancer - metabolism

* Authors contributed equally to this work.


 

  • References

  • 1 Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62 (1, Suppl) S47-S64
    CrossrefPubMedGoogle Scholar
  • 2 A brighter future in the fight against hepatitis. Nat Med 2013; 19 (07) 791
    CrossrefPubMedGoogle Scholar
  • 3 Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115 (02) 209-218
    CrossrefPubMedGoogle Scholar
  • 4 Mokdad AA, Lopez AD, Shahraz S. , et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014; 12: 145
    CrossrefPubMedGoogle Scholar
  • 5 Shi J, Hao A, Zhang Q, Sui G. The role of YY1 in oncogenesis and its potential as a drug target in cancer therapies. Curr Cancer Drug Targets 2015; 15 (02) 145-157
    CrossrefPubMedGoogle Scholar
  • 6 Donohoe ME, Zhang X, McGinnis L, Biggers J, Li E, Shi Y. Targeted disruption of mouse Yin Yang 1 transcription factor results in peri-implantation lethality. Mol Cell Biol 1999; 19 (10) 7237-7244
    CrossrefPubMedGoogle Scholar
  • 7 Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006; 25 (08) 1125-1142
    CrossrefPubMedGoogle Scholar
  • 8 Shang J, Zheng Y, Guo X. , et al. Hepatitis B virus replication and sex-determining region Y box 4 production are tightly controlled by a novel positive feedback mechanism. Sci Rep 2015; 5: 10066
    CrossrefPubMedGoogle Scholar
  • 9 Huang WH, Mai RT, Lee YH. Transcription factor YY1 and its associated acetyltransferases CBP and p300 interact with hepatitis delta antigens and modulate hepatitis delta virus RNA replication. J Virol 2008; 82 (15) 7313-7324
    CrossrefPubMedGoogle Scholar
  • 10 Riquet FB, Tan L, Choy BK. , et al. YY1 is a positive regulator of transcription of the Col1a1 gene. J Biol Chem 2001; 276 (42) 38665-38672
    CrossrefPubMedGoogle Scholar
  • 11 Galvin KM, Shi Y. Multiple mechanisms of transcriptional repression by YY1. Mol Cell Biol 1997; 17 (07) 3723-3732
    CrossrefPubMedGoogle Scholar
  • 12 Yant SR, Zhu W, Millinoff D, Slightom JL, Goodman M, Gumucio DL. High affinity YY1 binding motifs: identification of two core types (ACAT and CCAT) and distribution of potential binding sites within the human beta globin cluster. Nucleic Acids Res 1995; 23 (21) 4353-4362
    CrossrefPubMedGoogle Scholar
  • 13 Deng Z, Cao P, Wan MM, Sui G. Yin Yang 1: a multifaceted protein beyond a transcription factor. Transcription 2010; 1 (02) 81-84
    CrossrefPubMedGoogle Scholar
  • 14 Thomas MJ, Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key?. Gene 1999; 236 (02) 197-208
    CrossrefPubMedGoogle Scholar
  • 15 Nguyen N, Zhang X, Olashaw N, Seto E. Molecular cloning and functional characterization of the transcription factor YY2. J Biol Chem 2004; 279 (24) 25927-25934
    CrossrefPubMedGoogle Scholar
  • 16 Lee HY, Chaudhary J, Walsh GL, Hong WK, Kurie JM. Suppression of c-Fos gene transcription with malignant transformation of human bronchial epithelial cells. Oncogene 1998; 16 (23) 3039-3046
    CrossrefPubMedGoogle Scholar
  • 17 Nakanishi-Matsui M, Hayashi Y, Kitamura Y, Koike K. Integrated hepatitis B virus DNA preserves the binding sequence of transcription factor Yin and Yang 1 at the virus-cell junction. J Virol 2000; 74 (12) 5562-5568
    CrossrefPubMedGoogle Scholar
  • 18 Notarbartolo M, Giannitrapani L, Vivona N. , et al. Frequent alteration of the Yin Yang 1/Raf-1 kinase inhibitory protein ratio in hepatocellular carcinoma. OMICS 2011; 15 (05) 267-272
    CrossrefPubMedGoogle Scholar
  • 19 Yano Y, Utsumi T, Lusida MI, Hayashi Y. Hepatitis B virus infection in Indonesia. World J Gastroenterol 2015; 21 (38) 10714-10720
    CrossrefPubMedGoogle Scholar
  • 20 Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J 2013; 10: 239
    CrossrefPubMedGoogle Scholar
  • 21 Yang W, Mason WS, Summers J. Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus-infected liver. J Virol 1996; 70 (07) 4567-4575
    PubMedGoogle Scholar
  • 22 Yang W, Summers J. Infection of ducklings with virus particles containing linear double-stranded duck hepatitis B virus DNA: illegitimate replication and reversion. J Virol 1998; 72 (11) 8710-8717
    CrossrefPubMedGoogle Scholar
  • 23 Hayashi Y, Kitamura Y, Nakanishi M, Koike K. The binding site of transcription factor YY1 is required for intramolecular recombination between terminally repeated sequences of linear replicative hepatitis B virus DNA. J Virol 2000; 74 (20) 9471-9478
    CrossrefPubMedGoogle Scholar
  • 24 Huang YW, Liu JC, Deatherage DE. , et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 2009; 69 (23) 9038-9046
    CrossrefPubMedGoogle Scholar
  • 25 Zhang S, Kim K, Jin UH. , et al. Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells. Mol Cancer Ther 2012; 11 (01) 108-118
    CrossrefPubMedGoogle Scholar
  • 26 Shan X, Ren M, Chen K, Huang A, Tang H. Regulation of the microRNA processor DGCR8 by hepatitis B virus proteins via the transcription factor YY1. Arch Virol 2015; 160 (03) 795-803
    CrossrefPubMedGoogle Scholar
  • 27 Degasperi E, Aghemo A, Colombo M. Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clin Liver Dis 2017; 21 (03) 631-643
    CrossrefPubMedGoogle Scholar
  • 28 Lempp FA, Ni Y, Urban S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol 2016; 13 (10) 580-589
    CrossrefPubMedGoogle Scholar
  • 29 Friedman SL. Hepatic fibrosis: emerging therapies. Dig Dis 2015; 33 (04) 504-507
    CrossrefPubMedGoogle Scholar
  • 30 Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456
    CrossrefPubMedGoogle Scholar
  • 31 Natarajan V, Harris EN, Kidambi S. SECs (sinusoidal endothelial cells), liver microenvironment, and fibrosis. BioMed Res Int 2017; 2017: 4097205
    PubMedGoogle Scholar
  • 32 Karsenty G, de Crombrugghe B. Two different negative and one positive regulatory factors interact with a short promoter segment of the alpha 1 (I) collagen gene. J Biol Chem 1990; 265 (17) 9934-9942
    PubMedGoogle Scholar
  • 33 Saarela J, Rehn M, Oikarinen A, Autio-Harmainen H, Pihlajaniemi T. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol 1998; 153 (02) 611-626
    CrossrefPubMedGoogle Scholar
  • 34 Saarela J, Ylikärppä R, Rehn M, Purmonen S, Pihlajaniemi T. Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol 1998; 16 (06) 319-328
    CrossrefPubMedGoogle Scholar
  • 35 Armelin-Correa LM, Lin CJ, Barbosa A. , et al. Characterization of human collagen XVIII promoter 2: interaction of Sp1, Sp3 and YY1 with the regulatory region and a SNP that increases transcription in hepatocytes. Matrix Biol 2005; 24 (08) 550-559
    CrossrefPubMedGoogle Scholar
  • 36 Assy N, Minuk GY. Liver regeneration: methods for monitoring and their applications. J Hepatol 1997; 26 (04) 945-952
    CrossrefPubMedGoogle Scholar
  • 37 Moriya K, Sakai K, Yan MH, Sakai T. Fibronectin is essential for survival but is dispensable for proliferation of hepatocytes in acute liver injury in mice. Hepatology 2012; 56 (01) 311-321
    CrossrefPubMedGoogle Scholar
  • 38 Diamond RH, Du K, Lee VM. , et al. Novel delayed-early and highly insulin-induced growth response genes. Identification of HRS, a potential regulator of alternative pre-mRNA splicing. J Biol Chem 1993; 268 (20) 15185-15192
    PubMedGoogle Scholar
  • 39 Du K, Leu JI, Peng Y, Taub R. Transcriptional up-regulation of the delayed early gene HRS/SRp40 during liver regeneration. Interactions among YY1, GA-binding proteins, and mitogenic signals. J Biol Chem 1998; 273 (52) 35208-35215
    CrossrefPubMedGoogle Scholar
  • 40 Shi Y, Seto E, Chang LS, Shenk T. Transcriptional repression by YY1, a human GLI-Krüppel-related protein, and relief of repression by adenovirus E1A protein. Cell 1991; 67 (02) 377-388
    CrossrefPubMedGoogle Scholar
  • 41 Zhao X, Parpart S, Takai A. , et al. Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma. Oncogene 2015; 34 (39) 5095-5104
    CrossrefPubMedGoogle Scholar
  • 42 Tsang DP, Wu WK, Kang W. , et al. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma. J Pathol 2016; 238 (05) 651-664
    CrossrefPubMedGoogle Scholar
  • 43 Mai RT, Yeh TS, Kao CF, Sun SK, Huang HH, Wu Lee YH. Hepatitis C virus core protein recruits nucleolar phosphoprotein B23 and coactivator p300 to relieve the repression effect of transcriptional factor YY1 on B23 gene expression. Oncogene 2006; 25 (03) 448-462
    CrossrefPubMedGoogle Scholar
  • 44 Wang H, Yuan G, Zhao B, Zhao Y, Qiu Y. High expression of B23 is associated with tumorigenesis and poor prognosis in bladder urothelial carcinoma. Mol Med Rep 2017; 15 (02) 743-749
    CrossrefPubMedGoogle Scholar
  • 45 Zhou F, Chen E, You D, Song Y, Sun Z, Yue L. Both high expression of nucleophosmin/B23 and CRM1 predicts poorer prognosis in human gastric cancer. APMIS 2016; 124 (12) 1046-1053
    CrossrefPubMedGoogle Scholar
  • 46 Avdalyan AM, Kobyakov DS, Klimachev VV. , et al. Expression of B23/nucleophosphamine nonribosomal nucleolar protein in smooth muscle tumors of the corpus uteri. Bull Exp Biol Med 2015; 160 (02) 286-290
    CrossrefPubMedGoogle Scholar
  • 47 Yamashita T, Forgues M, Wang W. , et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68 (05) 1451-1461
    CrossrefPubMedGoogle Scholar
  • 48 Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007; 67 (22) 10831-10839
    CrossrefPubMedGoogle Scholar
  • 49 Yamashita T, Ji J, Budhu A. , et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136 (03) 1012-1024
    CrossrefPubMedGoogle Scholar
  • 50 Kondo Y, Shen L, Cheng AS. , et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40 (06) 741-750
    CrossrefPubMedGoogle Scholar
  • 51 Zhang S, Jiang T, Feng L. , et al. Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downregulation of CCAAT/enhancer-binding protein alpha. J Mol Med (Berl) 2012; 90 (09) 1069-1077
    CrossrefPubMedGoogle Scholar
  • 52 Eves EM, Shapiro P, Naik K, Klein UR, Trakul N, Rosner MR. Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol Cell 2006; 23 (04) 561-574
    CrossrefPubMedGoogle Scholar
  • 53 Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 2004; 91: 169-200
    PubMedGoogle Scholar
  • 54 Huerta-Yepez S, Vega M, Jazirehi A. , et al. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene 2004; 23 (29) 4993-5003
    CrossrefPubMedGoogle Scholar
  • 55 Tsai MF, Wang CC, Chang GC. , et al. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 2006; 98 (12) 825-838
    CrossrefPubMedGoogle Scholar
  • 56 Wang CC, Tsai MF, Hong TM. , et al. The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion. Oncogene 2005; 24 (25) 4081-4093
    CrossrefPubMedGoogle Scholar
  • 57 Wang CC, Tsai MF, Dai TH. , et al. Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1. Cancer Res 2007; 67 (10) 4816-4826
    CrossrefPubMedGoogle Scholar
  • 58 Zhang L, Cai X, Chen K. , et al. Hepatitis B virus protein up-regulated HLJ1 expression via the transcription factor YY1 in human hepatocarcinoma cells. Virus Res 2011; 157 (01) 76-81
    CrossrefPubMedGoogle Scholar
  • 59 Benn J, Su F, Doria M, Schneider RJ. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol 1996; 70 (08) 4978-4985
    PubMedGoogle Scholar
  • 60 Austen M, Cerni C, Lüscher-Firzlaff JM, Lüscher B. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc. Oncogene 1998; 17 (04) 511-520
    CrossrefPubMedGoogle Scholar
  • 61 Bannasch P. Glycogenotic hepatocellular carcinoma with glycogen-ground-glass hepatocytes: a heuristically highly relevant phenotype. World J Gastroenterol 2012; 18 (46) 6701-6708
    CrossrefPubMedGoogle Scholar
  • 62 Huang Q, Tan Y, Yin P. , et al. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res 2013; 73 (16) 4992-5002
    CrossrefPubMedGoogle Scholar
  • 63 Toshkov I, Chisari FV, Bannasch P. Hepatic preneoplasia in hepatitis B virus transgenic mice. Hepatology 1994; 20 (05) 1162-1172
    CrossrefPubMedGoogle Scholar
  • 64 Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev 2013; 23 (01) 53-62
    CrossrefPubMedGoogle Scholar
  • 65 Yang JC, Teng CF, Wu HC. , et al. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 2009; 49 (06) 1962-1971
    CrossrefPubMedGoogle Scholar
  • 66 Su IJ, Wang LH, Hsieh WC. , et al. The emerging role of hepatitis B virus pre-S2 deletion mutant proteins in HBV tumorigenesis. J Biomed Sci 2014; 21: 98
    CrossrefPubMedGoogle Scholar
  • 67 Teng CF, Wu HC, Shyu WC, Jeng LB, Su IJ. Pre-S2 mutant-induced mammalian target of rapamycin signal pathways as potential therapeutic targets for hepatitis B virus-associated hepatocellular carcinoma. Cell Transplant 2017; 26 (03) 429-438
    CrossrefPubMedGoogle Scholar
  • 68 Teng CF, Wu HC, Tsai HW, Shiah HS, Huang W, Su IJ. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. Hepatology 2011; 54 (04) 1199-1207
    CrossrefPubMedGoogle Scholar
  • 69 Teng CF, Hsieh WC, Wu HC. , et al. Hepatitis B virus Pre-S2 mutant induces aerobic glycolysis through mammalian target of rapamycin signal cascade. PLoS One 2015; 10 (04) e0122373
    CrossrefPubMedGoogle Scholar
  • 70 Gnanaprakasam JNR, Sherman JW, Wang R. MYC and HIF in shaping immune response and immune metabolism. Cytokine Growth Factor Rev 2017; 35: 63-70
    CrossrefPubMedGoogle Scholar
  • 71 Amann T, Hellerbrand C. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 2009; 13 (12) 1411-1427
    CrossrefPubMedGoogle Scholar
  • 72 Legry V, Schaap FG, Delire B, Horsmans Y, Leclercq IA. Yin Yang 1 and farnesoid X receptor: a balancing act in non-alcoholic fatty liver disease?. Gut 2014; 63 (01) 1-2
    CrossrefPubMedGoogle Scholar
  • 73 Lu Y, Ma Z, Zhang Z. , et al. Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. Gut 2014; 63 (01) 170-178
    CrossrefPubMedGoogle Scholar
  • 74 Preidis GA, Kim KH, Moore DD. Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance. J Clin Invest 2017; 127 (04) 1193-1201
    CrossrefPubMedGoogle Scholar
  • 75 Huang HY, Li X, Liu M. , et al. Transcription factor YY1 promotes adipogenesis via inhibiting CHOP-10 expression. Biochem Biophys Res Commun 2008; 375 (04) 496-500
    CrossrefPubMedGoogle Scholar
  • 76 Schlegel A. Studying non-alcoholic fatty liver disease with zebrafish: a confluence of optics, genetics, and physiology. Cell Mol Life Sci 2012; 69 (23) 3953-3961
    CrossrefPubMedGoogle Scholar
  • 77 Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol 2011; 8 (09) 491-501
    CrossrefPubMedGoogle Scholar
  • 78 Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141 (05) 1572-1585
    CrossrefPubMedGoogle Scholar
  • 79 Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endocannabinoids in liver disease. Hepatology 2011; 53 (01) 346-355
    CrossrefPubMedGoogle Scholar
  • 80 Miller LK, Devi LA. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev 2011; 63 (03) 461-470
    CrossrefPubMedGoogle Scholar
  • 81 Chanda D, Kim YH, Li T. , et al. Hepatic cannabinoid receptor type 1 mediates alcohol-induced regulation of bile acid enzyme genes expression via CREBH. PLoS One 2013; 8 (07) e68845
    CrossrefPubMedGoogle Scholar
  • 82 Winkler GS. The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol 2010; 222 (01) 66-72
    CrossrefPubMedGoogle Scholar
  • 83 Hwang SL, Kwon O, Kim SG, Lee IK, Kim YD. B-cell translocation gene 2 positively regulates GLP-1-stimulated insulin secretion via induction of PDX-1 in pancreatic β-cells. Exp Mol Med 2013; 45: e25
    CrossrefPubMedGoogle Scholar
  • 84 Lee SE, Hwang SL, Jang WG, Chang HW, Kim YD. B-cell translocation gene 2 promotes hepatic hepcidin production via induction of Yin Yang 1. Biochem Biophys Res Commun 2015; 460 (04) 996-1001
    CrossrefPubMedGoogle Scholar
  • 85 Kim YD, Hwang SL, Lee EJ. , et al. Melatonin ameliorates alcohol-induced bile acid synthesis by enhancing miR-497 expression. J Pineal Res 2017; 62: e12386
    CrossrefPubMedGoogle Scholar
  • 86 Jedlitschky G, Hoffmann U, Kroemer HK. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2006; 2 (03) 351-366
    CrossrefPubMedGoogle Scholar
  • 87 Grube M, Meyer Zu Schwabedissen H, Draber K. , et al. Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. Drug Metab Dispos 2005; 33 (01) 31-37
    PubMedGoogle Scholar
  • 88 Zollner G, Fickert P, Zenz R. , et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001; 33 (03) 633-646
    CrossrefPubMedGoogle Scholar
  • 89 Shoda J, Kano M, Oda K. , et al. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am J Gastroenterol 2001; 96 (12) 3368-3378
    CrossrefPubMedGoogle Scholar
  • 90 Chen HL, Liu YJ, Chen HL. , et al. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. Pediatr Res 2008; 63 (06) 667-673
    CrossrefPubMedGoogle Scholar
  • 91 Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol 2013; 58 (01) 155-168
    CrossrefPubMedGoogle Scholar
  • 92 Liu XC, Lian W, Zhang LJ. , et al. Interleukin-18 down-regulates multidrug resistance-associated protein 2 expression through farnesoid x receptor associated with nuclear factor kappa B and Yin Yang 1 in human hepatoma HepG2 cells. PLoS One 2015; 10 (08) e0136215
    CrossrefPubMedGoogle Scholar
  • 93 Her GM, Pai WY, Lai CY, Hsieh YW, Pang HW. Ubiquitous transcription factor YY1 promotes zebrafish liver steatosis and lipotoxicity by inhibiting CHOP-10 expression. Biochim Biophys Acta 2013; 1831 (06) 1037-1051
    CrossrefPubMedGoogle Scholar
  • 94 Yakovleva T, Kolesnikova L, Vukojević V. , et al. YY1 binding to a subset of p53 DNA-target sites regulates p53-dependent transcription. Biochem Biophys Res Commun 2004; 318 (02) 615-624
    CrossrefPubMedGoogle Scholar
  • 95 Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer 2012; 130 (08) 1715-1725
    CrossrefPubMedGoogle Scholar
  • 96 Wan M, Huang W, Kute TE. , et al. Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol 2012; 180 (05) 2120-2133
    CrossrefPubMedGoogle Scholar
  • 97 He G, Wang Q, Zhou Y. , et al. YY1 is a novel potential therapeutic target for the treatment of HPV infection-induced cervical cancer by arsenic trioxide. Int J Gynecol Cancer 2011; 21 (06) 1097-1104
    CrossrefPubMedGoogle Scholar
  • 98 Donia M, Maksimovic-Ivanic D, Mijatovic S. , et al. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle 2011; 10 (03) 492-499
    CrossrefPubMedGoogle Scholar
  • 99 Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 2005; 24 (55) 8114-8127
    CrossrefPubMedGoogle Scholar
  • 100 Wilkinson FH, Park K, Atchison ML. Polycomb recruitment to DNA in vivo by the YY1 REPO domain. Proc Natl Acad Sci U S A 2006; 103 (51) 19296-19301
    CrossrefPubMedGoogle Scholar